Moa Technology, the agricultural biotechnology company tackling herbicide-resistant weeds that threaten the world’s food security, has announced the appointment of Rob Quinn as Chief Financial Officer (CFO) and Apostolos Klontzaris as Chief Business Officer (CBO)
OMass Therapeutics, a biotechnology company at ARC Oxford identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, has announced the appointment of Melissa Faris as Chief Business Officer.
Oxford Nanopore and Day Zero Diagnostics have announced a collaboration to develop an end-to-end solution for the diagnosis of bloodstream infections, a leading cause of sepsis.
Breakthrough Properties has held groundbreaking events in October to herald the start of the construction of Trinity House by Breakthrough in one of the leading academic and innovation clusters in Oxford.
EDX Medical has completed the acquisition of Oxford-based Hutano Diagnostics and established a Point-of-Care Innovation team to expand and accelerate the range of Hutano Diagnostics’ new tests and their integration with EDX smartphone expertise.
Parkwalk has launched the University of Oxford Innovation Fund VI (UOIF VI), the sixth fund in a decade long partnership with Oxford University Innovation (OUI).
New research commissioned by Milton Park reveals that £2.14 billion of equity investment was generated across 272 companies based in the science, technology and business community over the past decade.
The facility has been designed by Foster + Partners and is devoted to reimagining and redefining cancer treatment whilst enhancing overall human health and global health policy.
There are significant opportunities for investors to meet growing demand from the life sciences sector, according to the 2023 Europe Life Sciences Cluster Outlook published by JLL – a leading real estate and investment management firm.
The early-stage drug discovery company with operations in Oxford and Boston is looking to increase its drug discovery and validation capabilities in key neuro disease areas.
The funding will help to develop a unique solution that will enhance the effect of post-surgical radiotherapy on aggressive brain tumours and reduce the chance of cancer regrowth.
The funding, over the next five years, was awarded to Oxford’s two National Institute for Health and Care Research (NIHR) Biomedical Research Centres (BRC).